Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months Ended September 30, 2023
Context: GSK reported strong year-to-date and Q3 performance, driven by broad-based execution and the successful launch of Arexvy, the world's first RSV vaccine for older adults. This performance prompted an upgrade to full-year 2023 guidance.
Key Financial Metrics
| Metric | Q3 2023 (£m) | Q3 Growth (CER%) | YTD 2023 (£m) | YTD Growth (CER%) |
|---|---|---|---|---|
| Turnover | 8,147 | 10% | 22,276 | 2% |
| Turnover ex COVID | 8,146 | 16% | 22,102 | 13% |
| Total Operating Profit | 1,949 | 83% | 6,172 | 39% |
| Adjusted Operating Profit | 2,772 | 15% | 7,034 | 10% |
| Adjusted Operating Margin | 34.0% | +1.7 ppts | 31.6% | +2.2 ppts |
| Total Continuing EPS | 36.1p | >100% | 113.0p | 59% |
| Adjusted EPS | 50.4p | 17% | 126.2p | 14% |
| Cash Generated from Operations | 2,508 | 32% | 4,415 | (24%) |
| Free Cash Flow (Continuing Ops) | 1,655 | >100% | 1,314 | (41%) |
| Total Net Debt | 17,589 | - | 17,589 | - |
Note: CER = Constant Exchange Rate. Growth figures exclude COVID-19 solutions unless otherwise noted.
Material Changes vs. Prior Period
- Revenue Growth: Total Q3 sales grew 10% at CER, with ex-COVID sales growing 16%. Vaccines sales surged 33% (34% ex-COVID), driven by Shingrix (+15%) and the new Arexvy launch (£0.7 billion). Specialty Medicines declined 1% total but grew 17% ex-COVID, led by HIV (+15%). General Medicines declined 2% due to generic competition, partially offset by Trelegy (+23%).
- Profitability: Total operating profit increased 83% at CER, significantly aided by lower charges for contingent consideration liabilities compared to Q3 2022. Adjusted operating profit grew 15% at CER, reflecting strong execution and higher royalty income, offset by increased R&D investment and a 7 percentage point reduction from lower COVID-19 sales.
- Regional Performance: The US region grew 19% at CER, Europe grew 5%, while International declined 2% at CER (though grew 17% ex-COVID).
- Legal Matters: GSK reached a confidential settlement in the Cantlay/Harper Zantac case and three remaining breast cancer bellwether cases in California, resulting in dismissal from these cases. The company does not admit liability.
Guidance, Outlook, and Risks
Full-Year 2023 Guidance Upgrade
GSK has upgraded its full-year 2023 guidance at Constant Exchange Rates (CER), excluding COVID-19 solutions:
- Turnover: Expected to increase 12% to 13% (previously 8% to 10%).
- Adjusted Operating Profit: Expected to increase 13% to 15% (previously 11% to 13%).
- Adjusted EPS: Expected to increase 17% to 20% (previously 14% to 17%).
Management Commentary
CEO Emma Walmsley highlighted "strong and sustained performance momentum" and "double-digit sales and earnings growth." The upgrade is supported by the successful US launch of Arexvy, with full-year sales expected between £0.9 billion and £1 billion. The company anticipates Arexvy sales will track in line with high-dose flu analogues.
Risks and Contingencies
- COVID-19 Impact: Lower sales of COVID-19 solutions reduced Adjusted Operating Profit growth by 7 percentage points in Q3. Full-year turnover growth is expected to be impacted by approximately 8% due to lower COVID sales.
- Legal Proceedings: Significant legal charges relate to Zantac litigation. While recent settlements were reached, the company faces ongoing trials in other jurisdictions starting in 2024.
- Exchange Rates: If exchange rates hold at September 30, 2023 levels, the estimated impact on 2023 Sterling turnover growth would be -2% and on Adjusted Operating Profit growth would be -4%.
Investor Verification Checklist
- Arexvy Trajectory: Verify if Arexvy sales continue to track with high-dose flu analogues as assumed in the £0.9-£1 billion full-year forecast.
- Shingrix US Performance: Monitor US Shingrix sales, which declined 6% CER in Q3 due to inventory dynamics and challenging comparators, despite strong growth in International and Europe.
- Zantac Litigation Costs: Track future legal provisions and settlement costs related to Zantac as trials proceed in 2024.
- General Medicines Decline: Assess the impact of generic competition on older products and the ability of Trelegy to offset these declines in the General Medicines portfolio.
- Contingent Consideration: Review fluctuations in contingent consideration liabilities (specifically ViiV Healthcare/Shionogi) which significantly impacted Total Operating Profit but are excluded from Adjusted metrics.